A股盘前市场要闻速递（2025-09-03）

Group 1: Central Bank and Policy Updates - The central bank reported a net liquidity injection of 300 billion yuan through Medium-term Lending Facility (MLF) in August, while 160.8 billion yuan was withdrawn via Pledged Supplementary Lending (PSL) [1] - A new tax policy was announced to support the transfer of state-owned equity and cash income to the social security fund, including exemptions from VAT and corporate income tax for the receiving entities [1] Group 2: Market Activity and Trends - In August, A-share new account openings reached 2.65 million, a year-on-year increase of 165.21%, significantly surpassing the previous year's figures [2] - The stock of Dongxin Co. will resume trading on September 3 after completing a review due to unusual trading fluctuations [3] - Kedi Co. announced that its robotics business is still in the development stage and has not yet generated revenue [4] Group 3: Company-Specific News - Zhejiang Rongtai responded to rumors regarding Tesla's optimistic production guidance for robots, stating they cannot confirm the accuracy of the information [5] - China National Petroleum Corporation plans to transfer 541 million shares (0.30% of total shares) to China Mobile Group, which will not change the controlling shareholder [6] - BeiGene highlighted the uncertainties in drug development due to the lengthy and costly nature of the biopharmaceutical industry [6] - Heng Rui Medicine received approval for clinical trials of its new anti-tumor drug HRS-7172 [7] - Daoshi Technology announced a $30 million investment in Brain Family Inc. for brain-computer interface technology [8] - Qingdao Bank's major shareholder plans to increase its stake by acquiring 233 million to 291 million shares [8] - Tianpu Co. warned of potential stock suspension if prices continue to rise abnormally [9] - Sailyus reported a 19.57% year-on-year increase in new energy vehicle sales for August [11] - CATL has repurchased 8.69 million shares for a total of 2.131 billion yuan [11] - Zhenyang Development is planning a share swap merger with Zhejiang Huhangyong, with a swap ratio of 1:1.08 [11] - Jingu Co. has developed structural components for intelligent robots using advanced materials, with plans for mass production [12] - Junshi Biosciences received approval for clinical trials of its JT118 injection, a vaccine for monkeypox [12]